BioAge Labs, Inc.

BioAge Labs, Inc.

BIOANYSE / NASDAQHealthcareSmall cap

$4.28-$0.43 (-9.1%)

Last close · Data as of Nov 20, 2026

Market cap
$756.6M
P/E
-9.4x
EV / EBITDA
-7.2x
Revenue
$9.0M
Net margin
-896.1%
ROCE
-33.8%

This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

BioAge Labs, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-23.0%
3M
-55.8%
6M
Hidden
1Y
Hidden
5Y
Short history
  • This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
  • A period is left blank when the price history is shorter than the period.

52-week range

This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.43 (-9.1%) from $4.71 to $4.28 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BIOA, bought on each weekday since 2024.

News & filings

What BioAge Labs filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 80.6 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • This period includes a one-day price step on 31 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Read moreShow less

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Sector
Healthcare
Shares outstanding
37.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$756.6M
P/E
-9.4x
P/B
2.8x
EV / EBITDA
-7.2x
EV / Sales
63.7x
P/S
84.1x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
-1031.5%
Net margin
-896.1%
EBITDA margin
-886.0%
ROE
-29.6%
ROCE
-33.8%
ROIC
-71.2%
ROA
-27.3%
Asset turnover
0.03

Growth

Revenue
$9.0M
Net profit growth, 1Y
13.4%
Free cash flow
-$82.3M

Solvency

Current ratio
14.24
Debt / Equity
0.02
Debt / Assets
0.02
CFO / Net profit
1.01
Cash / Market cap
25.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$9.0M
Gross profit$9.0M
Operating expenses$101.8M
Research and development$74.0M
Selling, general and administrative$27.8M
Operating income-$92.8M
Interest and other$12.2M
Pretax income-$80.6M
Tax and other$0.00
Net income-$80.6M

Revenue and net profit

Annual revenue, with net profit as the dashed line.

BioAge Labs, Inc. revenue and net profit by fiscal year
BioAge Labs, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$39.7M
FY2023$0.00-$63.9M
FY2024$0.00-$71.1M
FY2025$9.0M-$80.6M

Cash flows

FY2025: -$81.6M from operations, -$82.3M free after investment (dashed).

BioAge Labs, Inc. operating and free cash flow by fiscal year
BioAge Labs, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$36.2M-$36.3M
FY2023-$37.4M-$37.5M
FY2024-$51.5M-$51.9M
FY2025-$81.6M-$82.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$9.0M
EBITDA
-$79.7M
Net profit
-$80.6M
Cash from operations
-$81.6M
Free cash flow
-$82.3M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$9.0M-$79.7M-$80.6M-$82.3M-29.6%—+13.4%

Monthly returns

Month-by-month returns of BIOA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$294.9M
Liabilities$22.8M
Equity$272.1M
Paid-in capital$605.2M
Retained earnings-$333.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BIOA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. BioAge Labs, Inc. (this company)63.7x
  2. EVMN54.1x

Not shown (no positive earnings and no EV / Sales): Omeros Corporation, Bright Minds Biosciences Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
BioAge Labs, Inc.BIOAthis company$756.6M-9.4x2.8x-29.6%-7.2x
Eton Pharmaceuticals, Inc.ETON$791.6M-172.1x30.3x-17.6%249.0x
Phathom Pharmaceuticals, Inc.PHAT$786.4M-3.6x-1.8x50.5%-5.7x
Kura Oncology, Inc.KURA$778.6M—4.5x-160.0%—
Geron CorporationGERN$776.2M-9.3x3.4x-37.0%-16.5x
EVMNEVMN$745.2M-10.8x3.6x-33.5%-8.8x
Omeros CorporationOMER$741.8M-221.4x-6.1x2.8%-8.0x
HealthStream, Inc.HSTM$738.9M40.3x2.1x5.2%11.3x
Bright Minds Biosciences Inc.DRUG$731.0M-59.8x8.9x-14.9%-46.8x
Peer median—-10.8x3.5x-16.2%-8.0x

Year-to-date ROI

BIOA since 1 January, against earlier years.

Historical volatility

BIOA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

BioAge Labs, Inc. operating margin by fiscal year
BioAge Labs, Inc. operating margin by fiscal year
DateOperating margin
FY2025-1032.0%
LineFY2025
Operating expensesOperating Expense$101.8M
Research and developmentResearch And Development$74.0M
Total expensesTotal Expenses$101.8M
Pretax incomePretax Income-$80.6M

Learn while you research

Academy chapters picked for BioAge Labs, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →